Phase III Clinical Trial of Hepalatide in Patients With Chronic Hepatitis D

NCT07309380 | Not Yet Recruiting Phase 3

• 1 other identifier: L47-HD-II/III-01
• Study Type: interventional
• Target: 150
• Locations: 1 country
• Sites: 1

Brief Summary

This study adopts a multicenter, randomized, double-blind, placebo-parallel controlled design to evaluate the efficacy and safety of L47 in the treatment of chronic hepatitis D. A total of 150 subjects are planned to be enrolled. After passing the screening, they will be randomly assigned to the L47 group or the placebo group at a ratio of 2:1, with liver cirrhosis and subjects' regional distribution as stratification factors. The two groups will receive hepratide (2.1 mg/day) or placebo, respectively. Upon completion of the 48-week double-blind treatment phase, all subjects in each group can enter the open-label treatment follow-up phase, where they may voluntarily choose to receive L47 (2.1 mg/day) treatment or undergo follow-up observation only, until week 144. Subjects who discontinue treatment prematurely during the trial may also enter the open-label treatment follow-up phase. An interim analysis will be conducted after the subjects complete 24 weeks of trial treatment, with the comprehensive response rate at week 24 as the primary endpoint. The analysis will be performed by an independent statistical team. And the interim analysis results will be reviewed by the Independent Data Monitoring Committee (IDMC) . All subjects will complete the 48-week double-blind clinical trial. Throughout the entire study period, the safety of subjects will be closely monitored and evaluated, including the monitoring of adverse events (AEs) and other safety indicators.

Conditions

Hepatitis D, Chronic

Keywords

hepalatide; L47

Outcome Measures

Primary Outcomes (1)

• Proportion of subjects who achieved response

  HDV RNA suppression (\< LLOQ) or a decrease of ≥ 2 log10 from baseline combined with ALT normalization

  48 weeks of treatment

Secondary Outcomes (11)

• Proportion of subjects with a ≥ 2 log₁₀ decrease in HDV RNA from baseline

  48 weeks of treatment

• Proportion of subjects with a ≥ 2 log₁₀ decrease in HDV RNA from baseline and normalized ALT

  Continuous treatment for 48 weeks

• Proportion of subjects with HDV RNA below the limit of detection (LOD)

  Continuous treatment for 48 weeks

• Changes in HDV RNA relative to baseline

  Continuous treatment for 48 weeks

• Proportion of subjects with normalized ALT

  Continuous treatment for 48 weeks

Study Arms (2)

Group A

PLACEBO COMPARATOR

placebo of L47, sc,qd

Drug: Placebo of Hepalatide

Group B

EXPERIMENTAL

hepalatide 2.1mg, sc, qd, Continuous treatment for 48 weeks

Drug: Hepalatide 2.1mg

Interventions

Hepalatide 2.1mg DRUG

Continuous treatment with hepalatide 2.1mg sc, qd, for 48 weeks

Also known as: L47, HLT

Group B

Placebo of Hepalatide DRUG

Continuous treatment with placebo of hepalatide for 48 weeks

Group A

Eligibility Criteria

• Age: 18 Years - 65 Years
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Positive HBsAg or HBV DNA for at least 6 months (diagnosed as chronic hepatitis B), with stable nucleos(t)ide analogue (NA) treatment for ≥3 months prior to screening and documented HBV DNA suppression;
• Positive anti-HDV antibody (IgG and/or IgM) and at least two quantifiable HDV RNA measurements ≥3 months apart, with quantifiable HDV RNA at enrollment;
• ×ULN\< ALT\<10×ULN；
• No plan for pregnancy within 2 years; female subjects must not be pregnant or lactating, and all subjects must agree to use effective contraception during treatment and for 3 months after the last dose;
• No participation in other clinical trials within 3 months prior to screening;
• Good compliance with the study protocol;
• Ability to understand and willingness to sign the informed consent form (ICF).

You may not qualify if:

• Child-Pugh class C or Child-Pugh score ≥10;
• Subjects with any of the following conditions:
• History of severe decompensated liver disease, including moderate to severe ascites (grade 2 or 3), hepatic encephalopathy, gastrointestinal variceal bleeding, hepatorenal syndrome, etc., with an expected survival of less than 2 years;
• History of severe cardiac disease (including unstable or uncontrolled heart disease within the past 6 months, or New York Heart Association \[NYHA\] functional class III-IV);
• Uncontrolled epilepsy, severe psychiatric disorders, or a history of severe psychiatric disorders;
• History of organ transplantation;
• Diabetes mellitus or hypertension that is not adequately controlled;
• Presence of autoimmune diseases, immune-related extrahepatic manifestations (including vasculitis, purpura, polyarteritis nodosa, peripheral neuropathy, and glomerulonephritis), thyroid diseases, malignancies, or receipt of immunosuppressive therapy;
• Presence of serious underlying diseases such as severe infection, heart failure, chronic obstructive pulmonary disease, or other serious diseases;
• History of alcohol abuse or drug addiction.
• Total bilirubin \> 51 μmol/L, or serum albumin \< 28 g/L, or prothrombin time prolonged by \> 6 seconds;
• Creatinine clearance\<60mL/min；
• Co-infection with hepatitis A, C, or E virus, or HIV infection;
• Use of interferon within 3 months prior to screening;
• Positive pregnancy test in female subjects;

Sponsors & Collaborators

• Shanghai HEP Pharmaceutical Co., Ltd.: lead

Study Sites (1)

First Hospital of Jilin University

Changchun, Jilin, China

Location

MeSH Terms

Conditions

Hepatitis D, Chronic

Condition Hierarchy (Ancestors)

Hepatitis D; Hepatitis, Viral, Human; Virus Diseases; Infections; RNA Virus Infections; Hepatitis, Chronic; Hepatitis; Liver Diseases; Digestive System Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Junqi Niu, Professor

  The First Hospital of Jilin University

  STUDY CHAIR

• Yanhang Gao

  The First Hospital of Jilin University

  STUDY CHAIR

Central Study Contacts

Xiaolu Tang

CONTACT

86-21-68412368; tangxiaolu@heppharma.com

Xian Gao

CONTACT

gaoxian@heppharma.com

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 16, 2025
• First Posted: December 30, 2025
• Study Start: April 1, 2026
• Primary Completion (Estimated): June 1, 2027
• Study Completion (Estimated): August 1, 2027
• Last Updated: December 30, 2025

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)